How profitable is aTyr Pharma Inc. (ATYR)?

In FY 2025 (10-K), ATYR converted $1.0M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / ATYR / financials

BCDA (37) PASG (34) INTS (39) ABOS (33) ⌘ Pro Terminal →

aTyr Pharma Inc. (ATYR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.29 +27.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.59

aTyr Pharma Inc. (ATYR) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $12.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATYR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATYR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, aTyr Pharma Inc. (NASDAQ: ATYR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $6.29 (+27.33% 1D, market cap $12.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ATYR ranks #347 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATYR compare to BCDA and PASG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATYR carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCDA (BioCardia Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $13.0M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.1M). Among the 5-stock peer group, ATYR leads on earnings multiple (N/A) while ATYR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATYR?

▼

Per ATYR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339970), aTyr Pharma Inc. generated $190.0K in revenue (-19.1% YoY), -$74.1M in net income, and -$62.1M in free cash flow against $93.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.59 (+4.73%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATYR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY ATYR SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (30% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (28% of score)

FRED Regime × Technicals: 99% of 52W Range • RSI-14 at 89.3 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.25-32% Next Q

Q2 (-2Q)

Grade D$0.17+0% Next Q

Q3 (-1Q)

Grade D$0.17+3600% Next Q

Current

Grade D$6.29-6.1% Hist 90D α

Trajectory: E (38) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATYR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATYR currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.63) and Max Pain ($6.60) forces dealer call-delta covering toward $7.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATYR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATYR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ATYR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $353.0K

FY24

Rev $235.0K

FY25

Rev $190.0K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$190.0K	52%	-80%	-$74.1M	-$62.1M	-45%
FY 2024	$235.0K	52%	-80%	-$64.0M	-$69.2M	-45%
FY 2023	$353.0K	52%	-80%	-$50.4M	-$33.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATYR)

✓Walkthrough of ATYR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATYR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +648.81%▲ RESISTANCE BREAKOUT

2026-11-03O $5.37H $6.29L $4.94C $6.29VOL 126.6K

RES: $0.61SUP: $0.09SMA50: $0.63SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATYR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATYR Butterfly Map → + Track ATYR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. -19.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ATYR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATYR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATYR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATYR)

Health Care Rank #347 of 1015 ⚔️ BCDA vs ATYR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATYR vs. BCDA, PASG, INTS, ABOS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, aTyr Pharma Inc. (ATYR) ranks #347 by composite RQD confidence (46/100, grade D) and #873 by equity capitalization ($12.4M). Within this direct 5-issuer industry benchmark cohort, ATYR leads on earnings valuation at N/A trailing P/E, while ATYR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATYR ACTIVE aTyr Pharma Inc.	D	46/100	—	—	-35.0%	+27.33%	$12.4M	Benchmark Subject
BCDA BioCardia Inc.	D-	37/100	—	—	-35.0%	+4.75%	$13.0M	/bcda-vs-atyr →
PASG Passage Bio Inc.	E	34/100	—	—	-35.0%	-3.77%	$11.1M	/pasg-vs-atyr →
INTS Intensity Therapeutics Inc.	D-	39/100	—	—	-35.0%	+0.88%	$11.1M	/ints-vs-atyr →
ABOS Acumen Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	+14.09%	$15.2M	/abos-vs-atyr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001339970 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), aTyr Pharma Inc. (ATYR) reported GAAP revenue of $190.0K (-19.1% vs. FY2024 revenue of $235.0K , and -46.2% cumulative change since FY2023) , GAAP net income of -$74.1M, operating cash flow of -$62.0M, and free cash flow of -$62.1M (+10.3% YoY). On the balance sheet, ATYR closed FY2025 with $93.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$190.0K	-$74.1M	-$62.0M	-$62.1M	$93.0M	—
FY2024 (FY)	2024-12-31	$235.0K	-$64.0M	-$69.1M	-$69.2M	$96.8M	—
FY2023 (FY)	2023-12-31	$353.0K	-$50.4M	-$33.2M	-$33.2M	—	—

3. ATYR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATYR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ATYR compare to BCDA and PASG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ATYR?

Where is ATYR trading relative to its 50-day, 200-day, and 52-week technical levels?

ATYR last traded at $6.29 (+27.33% on volume of 336,724 shares), positioning the stock +898.41% above its 50-day simple moving average ($0.63) and +825.00% above its 200-day simple moving average ($0.68). Across its 52-week range of $0.10 to $5.43, ATYR sits at the 100.0% percentile with a 14-day RSI of 89.3 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.50 to $7.08).

Direct Sub-Reports: ATYR RQD Cockpit ATYR 12M Forecast ATYR Earnings & Move ATYR Dividends & DRIP ATYR Insiders & 13F ATYR Whale Options ATYR Profit Sankey ATYR News & Why

ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

ATYR — aTyr Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

aTyr Pharma Inc. (ATYR) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $6.29 (+27.33% 1D, market capitalization $12.4M).

Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (13/20) + Forensic Balance Sheet (7/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

ATyr Pharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Its market capitalization is $0.0B. Per the recent news wire, the company's experimental protein reduced lung fibrosis in a model, and aTyr expects to move it into testing in 2027. Revenue is minimal, reported at $0.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), aTyr Pharma Inc. (ATYR) reported $190.0K in annual revenue (up from $235.0K in FY2024, -19.1% YoY) and -$74.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($353.0K revenue, -$50.4M net income) through FY2025, ATYR scaled operating cash flow to -$62.0M and free cash flow to -$62.1M, backed by $93.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 14/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $0.10 – $5.43 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context is the Health Care classification and the Biological Products industry label. A prospective investor should note that the pipeline timeline (testing in 2027) implies the company's value depends on future clinical progress that the sources do not map to any partners, suppliers, or customers.

Key Question #1: Can ATYR sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $190.0K and free cash flow of -$62.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is ATYR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ATYR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for aTyr Pharma Inc. (ATYR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATYR Debate Forum (3) ↓

🟢 CATALYST TradingView • 21h ago

aTyr Pharma, Inc. Stock 12‑Month Price Target Raised to $3.2, Implies 1757% Upside

TradingView report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

aTyr Pharma (Nasdaq:ATYR) - Stock Analysis

Simply Wall St report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

aTyr Pharma announces 1-for-40 reverse stock split effective October 28

Investing.com report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GuruFocus • 1d ago

FEDERATED HERMES, INC. Trims aTyr Pharma Inc (ATYR) Stake -- Sha

GuruFocus report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

aTyr Pharma, Inc. (ATYR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An experimental protein reduced lung fibrosis in a model. aTyr expects to move it into testing in 2027.

Stock Titan report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

ATYR: Static price chart | aTyr Pharma | US0021202025

www.marketscreener.com report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

aTyr Pharma Announces One-for-40 Reverse Stock Split

GlobeNewswire report covering aTyr Pharma Inc. (ATYR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATYR Bull vs. Bear Conversation Board — What's Your Call at $6.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATYR 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $6.37 (+28.9%)

📌 Pinned Debate

Institutional accumulation and options positioning score 14 of 20, the strongest RQD pillar, alongside a reported price target raised t

The street is overcomplicating aTyr Pharma Inc. (ATYR). Institutional accumulation and options positioning score 14 of 20, the strongest RQD pillar, alongside a reported price target raised to $3.2.. With an RQD score of 46/100 (D) and Forensic Balance Sheet at 7/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $5.34.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 14/20 institutional whale-flow stock at $4.94 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $4.10 (-17.0%)

Spot @ $4.94

Operating income of -$77.6M in FY 2025 against a $13.5M market cap, with ROIC of -35%, FCF yield of 0%, and a Piotroski F-Score of 2/9.

I respect the product at aTyr Pharma Inc., but the stock at $4.94 is a different story. Operating income of -$77.6M in FY 2025 against a $13.5M market cap, with ROIC of -35%, FCF yield of 0%, and a Piotroski F-Score of 2/9.. FCF yield is 0.0% and RQD sits at 46/100 (D) — why pay up here when you can wait for next quarter's numbers?